文献速递乳腺癌头颈与中枢神经肿瘤

图卡替尼联合曲妥珠单抗和卡培他滨在HER2阳性转移性乳腺癌中维持生活质量:HER2CLIMB试验

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
PubMed 文献 · Eur J Cancer · 2021-06-29

HER2CLIMB试验中,图卡替尼联合曲妥珠单抗和卡培他滨显著改善HER2阳性转移性乳腺癌患者的无进展生存和总生存。本文评估图卡替尼对健康相关生活质量的影响,结果显示两治疗组EQ-VAS和EQ-5D-5L评分相似且稳定,图卡替尼组EQ-VAS有意义恶化风险降低19%,脑转移患者中降低49%。

要点

  • 图卡替尼联合方案维持了HER2阳性转移性乳腺癌患者的健康相关生活质量。
  • 脑转移患者中,图卡替尼组EQ-VAS有意义恶化风险降低49%。
  • 图卡替尼组至恶化时间未达到,安慰剂组为5.8个月(总体)和5.5个月(脑转移)。

核心结论

  • 在HER2阳性转移性乳腺癌患者中,图卡替尼联合曲妥珠单抗和卡培他滨治疗可维持健康相关生活质量,且在脑转移患者中维持时间更长。

研究设计与样本

  • HER2CLIMB试验为随机2:1分配图卡替尼或安慰剂联合曲妥珠单抗和卡培他滨,共364例患者符合HR-QoL评估条件,331例(91%)完成至少一次评估。

主要发现

  • 两治疗组基线EQ-VAS评分相似,并在整个治疗期间维持。
  • EQ-5D-5L评分在治疗组间相似,治疗期间稳定,停止治疗后恶化。
  • 图卡替尼组相比安慰剂组EQ-VAS有意义恶化(≥7分)风险降低19%(HR 0.81;95%CI 0.55, 1.18)。
  • 图卡替尼组至恶化中位时间未达到,安慰剂组为5.8个月(95%CI 4.3, -)。
  • 脑转移患者(n=164)中,图卡替尼组EQ-VAS有意义恶化风险降低49%(HR 0.51;95%CI 0.28, 0.93),至恶化中位时间未达到 vs 5.5个月(95%CI 4.2, -)。

关键数值与推荐

  • EQ-VAS有意义恶化定义为评分下降≥7分。
  • HR-QoL评估使用EQ-5D-5L问卷和EQ视觉模拟量表(VAS),从方案版本7开始,于第1周期第1天、第3-9周期每两周期、第12周期及之后每三周期、以及每位患者30天随访时进行。

临床怎么用

  • 对于HER2阳性转移性乳腺癌患者,尤其是脑转移患者,图卡替尼联合曲妥珠单抗和卡培他滨可在不损害生活质量的前提下提供生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In HER2CLIMB, tucatinib significantly improved progression-free and overall survival in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. We evaluated the impact of tucatinib on health-related quality of life (HR-QoL) in HER2CLIMB. METHODS: Patients were randomised 2:1 to tucatinib or placebo combined with trastuzumab and capecitabine. Starting with protocol version 7, the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire and EQ visual analogue scale (VAS) were administered at day 1 of cycle 1, every two cycles during cycles 3-9, every three cycles during cycle 12 and thereafter and at each patient's 30-day follow-up visit. RESULTS: Among 364 patients eligible for HR-QoL assessment, 331 (91%) completed ≥1 assessment. EQ-VAS scores were similar for both arms at baseline and maintained throughout treatment. EQ-5D-5L scores were similar between the treatment arms, stable throughout therapy and worsened after discontinuing treatment. Risk of meaningful deterioration (≥7 points) on EQ-VAS was reduced 19% in the tucatinib vs. placebo arm (hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.55, 1.18); the median (95% CI) time to deterioration was not reached in the tucatinib arm and was 5.8 months (4.3, -) in the placebo arm. Among patients with brain metastases (n = 164), risk of meaningful deterioration on EQ-VAS was reduced 49% in the tucatinib arm (HR: 0.51; 95% CI: 0.28, 0.93); the median (95% CI) time to deterioration was not reached in the tucatinib arm and was 5.5 months (4.2, -) in the placebo arm. CONCLUSIONS: HR-QoL was preserved for patients with HER2+ metastatic breast cancer who were treated with tucatinib added to trastuzumab and capecitabine and maintained longer with tucatinib therapy than without it among those with brain metastases. CLINICAL TRIAL REGISTRATION: NCT02614794.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mueller V, Wardley A, Paplomata E, et al. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). Eur J Cancer. 2021. PMID: 34214937. doi:10.1016/j.ejca.2021.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。